TwentyTwentyTweets
Tweets by 2020health-
Join 7,195 other subscribers
-
Recent Posts
Pages
Tag Archives: value-based pricing
Medical advisory body “NICE” should not spend too much time valuing drugs.
The UK National Institute for Health and Care Excellence (“NICE”) is currently holding a public consultation over its proposals for evaluating drugs. Drugs that are approved by NICE automatically become available for doctors to prescribe under the NHS throughout England … Continue reading
Posted in Business, CCGs, Commissioning, Department of Health, Drugs, Elderly, equality, Genetics, GPs, Health and Wellbeing, Health Bill, Health reform, Inequality, Innovation, Jeremy Hunt, NHS, NHS reforms, Patients, Pharma, Policy, Public Health, Research, Technology, Uncategorized, Wellbeing
Tagged 2020health, Clinical Commissioning Group, Commissioning, Department of Health, dose, elderly, General practitioner, government, GP, GPs, health, Health Bill, innovation, Jeremy Hunt, medicine, Medicines and Healthcare products Regulatory Agency, MHRA, National Health Service, National Institute for Health and Care Excellence, NHS, NICE, Old age, patient, Patients, pharmaceutical, PPRS, pricing, Proportionate QALY, Public Health, QALY, R&D, Research, value-based, value-based pricing
Leave a comment
Guest Blogspot: Negotiations with the UK Government over pharmaceutical pricing have achieved a good result for patients, the NHS and the industry.
The UK Government and the pharmaceutical industry shared many objectives throughout the recent drug pricing negotiations. For example, there was always broad agreement that: The total future drug bill needed to be affordable in the context of other spending in … Continue reading
Posted in Andrew Lansley, Business, Cancer, Department of Health, Drugs, Innovation, Jeremy Hunt, NHS, Patients, Pharma, Research, Smoking ban
Tagged 2020health, Andrew Lansley, Department of Health, Drugs, government, innovation, Jeremy Hunt, National Health Service, NHS, NICE, parallel export, parallel imporrt, patient, Patient Access Scheme, Patients, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing, VBP
1 Comment
Bad for patients and bad for growth?
2020health today publish a review from a patient’s perspective of the Government’s plans to change the way medicines are priced. Featured in today’s FT (£) we point out that patients are usually blissfully unaware of pricing negotiations but the Government’s … Continue reading
Guest Blogspot: Waiting for Decisions on UK Pharmaceutical Pricing
Little has been heard over how confidential talks between the Government and the pharmaceutical industry are progressing towards the goal of having a new, voluntary UK drug pricing system in place in 2014. In the eyes of the pharmaceutical companies … Continue reading
Posted in Andrew Lansley, Business, Children, Commissioning, David Cameron, Department of Health, Drugs, Emerging technologies, equality, Health and Wellbeing, Innovation, Jeremy Hunt, Uncategorized, Wellbeing
Tagged 2020health, Andrew Lansley, Bowel Cancer UK, Cancer Research UK, Drugs, government, innovation, medicine, Multiple Sclerosis Society, pharmaceutical, R&D, value-based, value-based pricing
1 Comment
Guest Blogspot: Think carefully about value-based drug pricing in the UK and let common sense prevail.
David Cameron and Jeremy Hunt share an important skill. They both have firsts from Oxford in Politics, Philosophy and Economics (PPE). I am not the greatest fan of this course because I would like to see more scientists, engineers and … Continue reading
Posted in Business, competition, David Cameron, Department of Health, Drugs, Election, Jeremy Hunt, NHS, Patients, Pharma, Policy, Primary Care
Tagged 2020health, block-buster, competition, David Cameron, demand, Department of Health, drug pricing system, Drugs, elderly, GP, GPs, Health Bill, innovation, medicine, National Health Service, NHS, NICE, parallel exports, parallel imports, patient, Patients, pharmaceutical, Philosophy and Economics, Politics, PPE, PPRS, pricing, quality of life, R&D, reference price, Research, value-based, value-based pricing, VBP
Leave a comment
Guest Blogspot: A wrong decision on UK drug pricing could seriously undermine all the good work that HM Treasury and the Department for Business, Innovation and Skills have done to encourage the UK pharmaceutical industry.
The recent local elections highlight the political dangers ahead. The current UK coalition government has lost popularity through decisions that do not all relate to austerity measures. Shortly after the General Election Andrew Lansley’s plans to increase the say of … Continue reading
Posted in Andrew Lansley, Business, Department of Health, Drugs, Election, Global Health, Health Bill, NHS, Patient choice, Patients, Pharma, Policy, Research, Technology
Tagged 2020health, Andrew Lansley, AstraZeneca, Department of Health, Drugs, GlaxoSmithKline, GSK, health, Health Bill, innovation, medicine, National Health Service, NHS, NICE, patient, Patients, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing
Leave a comment
Guest Blogspot: Pharmaceutical R & D – the value of radical innovation versus incremental progress
What we really want is affordable products that benefit patients, whether or not they are “innovative” in the usual sense of the word. Scientific innovation is not a medical end in itself. The ultimate aim of pharmaceutical R&D is to … Continue reading
Posted in Business, competition, Department of Health, Drugs, Emerging technologies, Finance, Healthcare, Innovation, NHS, Patients, Pharma, Policy, Research, Technology, Uncategorized
Tagged 2020health, Alderlin, angina, atenolol, beta-blocker, cimetidine, competition, David Jack, definition of innovation, Department of Health, Drugs, Eraldin, government, heart drug, incremental, Inderal, innovation, innovative, James Black, medicine, Michael Rawlins, National Health Service, NHS, NICE, patient, Patients, pharmaceutical, practolol, pricing, pronethalol, propranolol, R&D, ranitidine, Research, Sir David Jack, Sir James Black, Sir Michael Rawlins, Tagamet, Tenormin, ulcer drug, value-based, value-based pricing, Zantac
Leave a comment
Political Mood Change over the NHS, Innovation and the Pharmaceutical Industry in 2011
As 2011 draws to a close now is a good time to reflect on the period since the last UK General Election in 2010. We must consider what we have done right, what we have done wrong and what remains … Continue reading
Posted in Business, David Cameron, Department of Health, Drugs, Election, Genetics, Health Bill, Health Team, Hospitals, Innovation, NHS, Pharma, Policy, Research
Tagged 2020health, David Cameron, Department of Health, Drugs, genetics, government, GPs, Health Bill, innovation, medicine, National Health Service, NHS, NICE, Pfizer, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing
Leave a comment
Parallel importing and exporting of pharmaceuticals severely limits the options in designing an effective UK drug pricing scheme.
A fundamental principle of the EU is the establishment of a single market where products can be freely imported and exported between member states. In the case of pharmaceuticals this ideal conflicts with the freedom of individual countries to fix … Continue reading
Posted in Business, competition, Department of Health, Drugs, Innovation, NHS, Pharma, Policy, Research
Tagged 2020health, competition, Department of Health, Drugs, German pricing, innovation, Lilly, medicine, National Health Service, NHS, NICE, Novartis, parallel exporting, parallel importing, parallel trade, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing
1 Comment
Guest Blogspot: What should we expect from medical and pharmaceutical R&D in the future?
Charities representing patients with different illnesses compete to make the case for research and the availability of the best treatment and care in their areas of interest. The autumn party political conferences probably represent the peak campaigning period. Many medical … Continue reading
Posted in Business, Department of Health, Drugs, Emerging technologies, Hospitals, Innovation, mental health, NHS, Patients, Pharma, Policy, Research, Technology
Tagged 2020health, cancer, charities, Department of Health, Drugs, innovation, lupus, medicine, mental health, mergers, National Health Service, NHS, NICE, pharmaceutical, pricing, R&D, Research, think tank, value-based, value-based pricing
Leave a comment
2020health's Blog 
You must be logged in to post a comment.